New thoughts – recent data

Dr Linda PorterMCRN, West Midlands

WM-MCRN recruitment 2012/13

WM-CLRN PSG recruitment 2012/13

MCRN national performance metrics2012/13 (Q4 final draft)

A (Industry)

B (Public+CTU)

C (Public)

Target

HLO2Time and Target recruitment

80% 100% 100% 80%

HLO4Time for NHS permission

24% 80%

HLO5Time for first

patient recruited55% 25% 38% 80%

FY 2012/13 HLO2Studies closed to recruitment

WM-Central (Public) WM-Central (Industry)

WM-MCRN studies closed to recruitment2012/13

WM-MCRN studies closed to recruitment2012/13

Burton WAITUHNS Sabre, SLEEPS, WAITBWH I2S2HEFT I2S2, TrophosSWBH MCRN074(Xalatan) I2S2

UHCW I2S2, WAIT

WM-MCRN studies closed to recruitment2012/13

MCRN revised feasibility process

Timelines aimed at attracting Industry to the UK

LRNs = ‘ADDED VALUE’

Feasibility underpins performance

� Speed of set-up and delivering to target

•Early feedback (Max 10 working days)

•Site intelligence (within 15 working days)

Form return 3 – 7 working days

•Site identification (within 15 working days)

Form return 8 – 12 working days

What impacts on HLOs for MCRN?Feasibility

�rare studies (<12 patients per year in the UK)

�paediatric study design

�timing of clinics and appropriateness of bringing patients in within 30 days for registries vs interventional trials

�percentage of industry studies in the portfolio

�competitive recruitment

�paediatric pharmacy

�engagement with CTUs

WM process has embraced the LRN role

Sensitivities!

Studies in set up 2012/13HLO4: Time for NHS permission

Studies in set up 2012/13HLO5: First patient recruited

Studies in set up 2013HLO4: Time for NHS permission

Studies in set up 2013HLO5: First patient recruited

2013

Closed Jan-June 2013 Closing in next 3 months

Open & recruiting studies 2013/14

2013/14 Data and Thoughts ……

Children's research portfolio

�Now and post-transition

� NIHR networks aim to facilitate, promote and engage in high quality research collaborations

�EUROPAIN:

�UK leading recruiter with 2,619 of 6,446 internationally

�MCRN success included opening the study across the UK and WM region, short set-up timeline, working with new teams, delivering research in PICUs, making research available to neonates